Menopausal hyperinsulinism and hypertension – new approach

References

• Prior JC, Naess M, Langhammer A, et al. Ovulation prevalence in women with spontaneous normal length menstrual cycles - a population based cohort. HUNT 3, Norway. PLoS One. 2015;10(8):e01 34473.
   Web of Science ®Google Scholar
• Vujovic S, Ivovic M, Tancic Gajic M, et al. How to prevent cardiovascular disorders: influence of gonadal steroids on the heart. In: Birkhauser M, Genazzani AR, editors. Pre-menopause, menopauase and beyond, frontiers in gynecological endocrinology. Vol. 5. Berlin, Germany: Springer; 2018. p. 195–205.
   Google Scholar
• Pimenta E. Hypertension in women. Hypertens Res. 2012;35(2):148–152.
   PubMed Web of Science ®Google Scholar
• World Health Organization. World health statistic. A snapshot of global health. Geneva, Switzerland: World Health Organizartion; 2012. Available from http:/apps.who.int/iris/bitstream/10665.70889/a/WHOierhis12.1eng.pdf
   Google Scholar
• Coylewright M, Reckelhoff JF, Ouyang P. Menopause and hypertension: an age-old debate. Hypertension. 2008;51(4):952–999.
   PubMed Web of Science ®Google Scholar
• Park YW, Zhu S, Palaniappan L, et al. The metabolic syndrome prevalence and associated risk factors finding in the US population for the 3.health and nutritional examinating survey. Arch Intern Med. 2003;163(4):427–432.
   PubMedGoogle Scholar
• Viel EL, Lemariae CA. Immune regulation and vascular inflammation in genetic hypertension. Am J Physiol Heart Circ Physiol. 2010;298:938–944.
   PubMed Web of Science ®Google Scholar
• Lee HY, Després JP, Koh KK. Perivascular adipose tissue in the pathogenesis of cardiovascular disease. Atherosclerosis. 2013;230(2):177–184.
   PubMed Web of Science ®Google Scholar
• Slijepcevic DS. Ed. Sekanic D. Kremen. 1993. Beograd.
   Google Scholar
• Zhang XM. Organic reaction mechanism 2013: annual survey covering the literature. In: Knipe  editor. Hoboken (NJ): Wiley.
   Google Scholar
• Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365(9468):1415–1428.
   PubMed Web of Science ®Google Scholar
• Genevieve A. Lipids, menopause and early atherosclerosis in SWAN. Heart Wom Menopause. 2011;18:376–384.
   PubMed Web of Science ®Google Scholar
• Yan H, Yang W, Zhou F, et al. Estrogen improves insulin sensitivity and suppresses gluconeogenesis via the transcription factor foxo1. Diabetes. 2019;68(2):291–304.
   PubMed Web of Science ®Google Scholar
• Stubbins RE, Holcomb VB, Hong J, et al. Estrogen modulates abdominal adiposity and protects female mice from obesity and impaired glucose tolerance. Eur J Nutr. 2012;51(7):861–870.
   PubMed Web of Science ®Google Scholar
• Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000;62(1):29–38.
   PubMed Web of Science ®Google Scholar
• Paoletti AM, Cagnacci A, Di Carlo C. Clinical effect of hormonal replacement therapy with estradiol associated with noretisterone or drospirenone. A prospective randomized placebo controlled study. Gynecol Endocrinol. 2015;31:384–387.
   PubMed Web of Science ®Google Scholar
• De Franciscis P, Mainini G, Labriola D, et al. Low-dose estrogen and drospirenone combination: effects on metabolism and endothelial function in postmenopausal women with metabolic syndrome. Clin Exp Obstet Gynecol. 2013;40(2):233–235.
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Mannella P, Simoncini T. Drospirenone and its antialdosterone properties. Climacteric. 2007;10(1):11–18.
   PubMedGoogle Scholar
• Battaglia C, Cianciosi A, Mancini F, et al. Angeliq vs. Activelle in normotensive postmenopausal women: a prospective randomized pilot study. Menopause. 2009;16(4):803–809.
   PubMed Web of Science ®Google Scholar
• Zhau X, Yu J. Drospirenone with estradiuol for postmeopausal women with hypertension. J Hypert. 2016;34:28–34.
   Google Scholar
• Diaf M, Khaled BM, Sellam F. Impact of corpulence parameters and haemoglobin A1c on metabolic control in type 2 diabetic patients: comparison of apolipoprotein B/A-I ratio with fasting and postprandial conventional lipid ratios. Libyan J Med. 2015;10(1):27400.
   PubMed Web of Science ®Google Scholar
• Bitoska I, Krstevska B, Milenkovic T, et al. Effects of hormone replacement therapy on insulin resistance in postmenopausal diabetic women. Open Access Maced J Med Sci. 2016;4(1):83–88.
   PubMedGoogle Scholar
• Chen J, Gu D, Huang J, et al. Metabolic syndrome and salt sensitivity of blood pressure in non diabetic people in China: a dietary intervention study. Lancet. 2009;373(9666):829–835.
   PubMed Web of Science ®Google Scholar
• Oh GC, Kang KS, Park CS, et al. Metabolic syndrome, not menopause, is a risk factor for hypertension in perimenopausal women. Clin Hypertens. 2018;24(1):14–20.
   PubMedGoogle Scholar
• Rey Y. Association of menopause and type 2 diabetes. Menopause. 2020;26:325–330.
   Web of Science ®Google Scholar
• Mauvais Jarvis F. Menopause hormone therapy and type 2 diabetes prevention evidence: mechanisms and clinical implications. Endocrinol Rev. 2017;38:173–188.
   PubMed Web of Science ®Google Scholar
• Stamatelopoulos K, Papavagelis C, Augoulea A, et al. Dietary patterns and cardiovascular risk in postmenopausal women: protocol of a cross-sectional and prospective study. Maturitas. 2018;116:59–65.
   PubMed Web of Science ®Google Scholar
• Cannoletta M, Cagnacci M. Modification of blood pressure in postmenopausal women: role of hormone replacement therapy. J Women’s Health. 2014;6:745–757.
   Google Scholar
• Gambacciani M, Rosano G, Cappagli B, et al. Clinical and metabolic effects of drospirenone and estradiol in menopausal women: a prospective study. Climacteric. 2011;14(1):18–24.
   PubMed Web of Science ®Google Scholar
• White WB, Hanes V, Mallareddy M, et al. Effects of a new hormone therapy. Drospirenone and 17 beta estradiol in early morning blood pressure in postmenopausal women with hypertension. Hypertension. 2008;2(1):20–27.
   Web of Science ®Google Scholar
• Kannel WB. Prevalence implications of uncontrolled systolic hyprtension. Drug Aging. 2003;20:277–280.
   PubMed Web of Science ®Google Scholar
• Zhao X, Zhang XF, Zhao Y, et al. Effect of combined drospirenone with estradiol for hypertensive postmenopausal women: a systemic review and meta-analysis. Gynecol Endocrinol. 2016;32(9):685–689.
   PubMed Web of Science ®Google Scholar
• Preston RA. Comparative effects of conventional vs. novel hormone replacement therapy on blood pressure in postmenopausal women. Climacteric. 2009;12(1):66–70.
   PubMedGoogle Scholar
• Vitale C, Gambacciani M. Effects of hormone replacement therapy with anti-mineralocorticoid progestin drospirenone compared to tibolone on endothel function and central haemodynamics in postmenopausal women. Int J Cardiol. 2016;227:217–221.
   PubMed Web of Science ®Google Scholar
• Mansoor GA, McCabe EJ, White WB. Long-term reproducibility of ambulatory blood pressure. J Hypertens. 1994;12(6):703–708.
   PubMed Web of Science ®Google Scholar
• Stevenson J. The true risk of hormone replacement therapy. Pre-menopause, menopuase and beyond. In: Birkhauser M, Genazzani AR, editors. Frontiers in gynecological endocrinology. Vol. 5. Berlin, Germany: Springer; 2018, p. 245–252.
   Google Scholar
• Gerval M, Stevenson J. Establishing the risk related to hormone replacement therapy and cardiovascular disease in women. Clin Pharm. 2017;9(1). doi:10.1211/CP.2077.20202066
   Google Scholar